SOM 1311
Alternative Names: SOM-1311Latest Information Update: 29 Apr 2024
At a glance
- Originator SOM Biotech
- Class Small molecules
- Mechanism of Action Phenylalanine hydroxylase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Phenylketonuria
Highest Development Phases
- Preclinical Phenylketonuria
Most Recent Events
- 29 Apr 2024 SOM Biotech plans a phase IIa trial for Phenylketonuria in 2024 (SOM Biotech pipeline, April 2024)
- 01 Mar 2023 SOM Biotech plans a phase IIa trial for Phenylketonuria in Spain (SOM Biotech pipeline, March 2023)
- 27 Oct 2020 SOM 1311 is available for licensing as of 27 Oct 2020. https://sombiotech.com/partnership-with-som-biotech/ (SOM Biotech website, October 2020)